You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 360 A phase 1 study of an Off-the-Shelf, multi-neoantigen vector (ADXS-503) alone and in combination with pembrolizumab in subjects with metastatic non-small cell lung cancer (NSCLC)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
360 A phase 1 study of an Off-the-Shelf, multi-neoantigen vector (ADXS-503) alone and in combination with pembrolizumab in subjects with metastatic non-small cell lung cancer (NSCLC)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020291022
Dec 20202109
Jan 20213001
Feb 20212002
Mar 20213804
Apr 20216007
May 20211006
Jun 2021003
Jul 2021004
Aug 2021004
Sep 2021004
Oct 20211004
Nov 20212802
Dec 20211401
Jan 2022800
Feb 20221001
Mar 20221003
Apr 20227806
May 20224807
Jun 20223004
Jul 20228401
Aug 20222603
Sep 20222600
Oct 20222200
Nov 20221201
Dec 20221602
Jan 20231400
Feb 20233001
Mar 20232603
Apr 20231004
May 20231200
Jun 20232003
Jul 20232003
Aug 20231002
Sep 20231401
Oct 20232803
Nov 20234802
Dec 20234602
Jan 20243004
Feb 20241201
Mar 20243004
Apr 20241801
May 20242805
Jun 20242800
Jul 20241800
Aug 20241400
Sep 20242604
Oct 20242403
Nov 20244307
Dec 20241804
Jan 20253807
Feb 2025001
Apr 2025004
May 2025007
Jun 2025005
Total14970182